All 2024 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

123456下一頁 >

• 2024/06/21 Orphan drug designated D07001 heading to global phase 3 pivotal study
• 2024/01/18 Innopharmax's product Innomustine® has been approved for benefit coverage by National Health Insurance (NHI), and can be used in
• 2022/08/29 InnoPharmax have signed supplementary agreement with Shandong New Times Pharmaceuticals for Sapropterin Dihydrochloride.
• 2022/03/29 Patent of “Oral Administration of Unstable or Poorly-Absorbed Drugs (N11005)” was granted in U.S.
• 2022/02/10 First-Patient-In (FPI) of N11005-Oral Insulin Investigator-Initiated-Trial (IIT).
• 2022/01/18 InnoPharmax have entered supply contract with Astellas in Germany for the Bendamustine.
• 2021/12/23 InnoPharmax is invited to participate in the online corporate presentation held by Yuan Fu Securities..
• 2021/12/07 InnoPharmax have signed contract with Ainos Inc. for the development and distribution of oral antiviral treatment.
• 2021/10/04 D07001 (GemOral) Phase II/III clinical trial in humans for advanced bile duct cancer (Project No. INNO-GO-05) has been approved
• 2021/09/29 Investigator-Initiated-Trial (IIT) of N11005-Oral insulin formulation is under reviewed by IRB at Gan Nan Hospital.

123456下一頁 >